Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | December 31, 2022 | February 03, 2023 |
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director · Chief Executive Officer | December 21, 2021 | December 23, 2021 |
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 03, 2026 | June 05, 2026 |
| Hemab Therapeutics Holdings, Inc.COAG · Entity 4476 | Director | January 29, 2026 | May 04, 2026 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director | June 24, 2026 | June 25, 2026 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | June 29, 2023 | July 03, 2023 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | Director | July 01, 2026 | July 06, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Director | September 14, 2017 | September 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date December 31, 2022 · Filed February 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 28,528 |
Reported balance
After 2022-09-20 transaction · row 1
1 source rowRow 1 · 2022-09-20 · Gift · Disposed 1,500 · Balance 28,528 F1: This disposition reflects a bona fide gift of 1,500 shares to charity. |
Filing footnotes · ownership attribution and instrument terms
F1: This disposition reflects a bona fide gift of 1,500 shares to charity.
ALNYLAM PHARMACEUTICALS, INC.
Report date December 21, 2021 · Filed December 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 227,663 |
Ending reported balance
After 2021-12-22 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-12-21 · Grant · Acquired 14,167 · Balance 234,299 F1: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021. Row 2 · 2021-12-22 · Tax withholding · Disposed 6,315 · Balance 227,984 F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Row 3 · 2021-12-22 · Tax withholding · Disposed 2 · Balance 227,982 F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Row 4 · 2021-12-22 · Tax withholding · Disposed 319 · Balance 227,663 F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 3,133 |
Reported balance
Holding disclosure · report date 2021-12-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,133 F3: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021.
F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
F3: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Beam Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.55 · Expires 2036-06-03 | Direct | 19,676 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 19,676 · Balance 19,676 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Hemab Therapeutics Holdings, Inc.
Report date January 29, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,948 |
Ending reported balance
After 2026-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-04 · Conversion · Acquired 17,974 · Balance 17,974 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. Row 2 · 2026-05-04 · Conversion · Acquired 17,974 · Balance 35,948 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2036-01-28 | Direct | 107,338 |
Reported balance
After 2026-01-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-29 · Grant · Acquired 107,338 · Balance 107,338 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-04 · Conversion · Disposed 817 · Balance 0 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. F2: Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-04 · Conversion · Disposed 817 · Balance 0 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. F2: Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
F2: Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Kymera Therapeutics, Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23 | Direct | 6,068 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
PROKIDNEY CORP.
Report date June 29, 2023 · Filed July 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2033-06-29 | Direct | 48,128 |
Reported balance
After 2023-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-29 · Grant · Acquired 48,128 · Balance 48,128 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
TAKEDA PHARMACEUTICAL CO LTD
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,400 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 3,800 · Balance 10,400 F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029. F2: Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Disposition to issuer · Disposed 1,152 · Balance 0 F3: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10. F4: The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,883 to JPY 5,045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2029-06-01 | Direct | 1,319 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Grant · Acquired 1,319 · Balance 1,319 F5: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. |
| American Depositary SharesSEC Table I · non-derivative | Direct | 13,800 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,800 F2: Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029.
F2: Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs.
F3: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10.
F4: The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,883 to JPY 5,045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
bluebird bio, Inc.
Report date September 14, 2017 · Filed September 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,843 |
Ending reported balance
After 2017-09-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-09-14 · Exercise / conversion · Acquired 18,868 · Balance 24,711 Row 2 · 2017-09-14 · Sale · Disposed 18,268 · Balance 6,443 F1: The range in prices for the transaction reported on this line was $130.80 to $131.75. The average weighted price was $131.1935. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2017-09-14 · Sale · Disposed 600 · Balance 5,843 F2: The range in prices for the transaction reported on this line was $131.80 to $131.90. The average weighted price was $131.8167. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.09 · Expires 2022-01-08 | Direct | 0 |
Reported balance
After 2017-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-09-14 · Exercise / conversion · Acquired 18,868 · Balance 0 F3: This option vests in 48 equal monthly installments, commencing on April 1, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: The range in prices for the transaction reported on this line was $130.80 to $131.75. The average weighted price was $131.1935. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2: The range in prices for the transaction reported on this line was $131.80 to $131.90. The average weighted price was $131.8167. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: This option vests in 48 equal monthly installments, commencing on April 1, 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2020 Filed Aug 21, 2020 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 34,765 | $9.14 | $317,752.10 |
DisclosureSEC source: 0001735276-20-000095 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000050 · wf-form4_159104594054176.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000050 · wf-form4_159104594054176.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000050 · wf-form4_159104594054176.xml · derivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,686 Underlying: Common stock · 1,686 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 8,096 | $0.00 Strike: $53.35 | $0.00 |
DisclosureSEC source: 0001439222-20-000050 · wf-form4_159104594054176.xml · derivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,096 Underlying: Common stock · 8,096 shares Expires 2030-05-28 F2 · derivative.exercise_date: This option was granted on May 28, 2020. This option vests as to 100% of the underlying shares on May 28, 2021. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 34,765 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001735276-20-000062 · edgardoc.xml · derivative · entry 6 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,530 Underlying: Common Stock · 34,765 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F6 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5,013 | $144.33 | $723,526.29 |
DisclosureSEC source: 0001735276-20-000062 · edgardoc.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,589 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F4 · price: Sale prices ranged from $143.92 to $144.92. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 16,315 | $143.46 | $2,340,549.90 |
DisclosureSEC source: 0001735276-20-000062 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,602 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F3 · price: Sale prices ranged from $142.92 to $143.91. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 13,437 | $142.51 | $1,914,906.87 |
DisclosureSEC source: 0001735276-20-000062 · edgardoc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,917 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F2 · price: Sale prices ranged from $141.92 to $142.89. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:03 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 34,765 | $9.14 | $317,752.10 |
DisclosureSEC source: 0001735276-20-000062 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 256 | $106.27 | $27,205.12 |
DisclosureSEC source: 0001735276-20-000046 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,589 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 6,315 | $104.75 | $661,496.25 |
DisclosureSEC source: 0001735276-20-000046 · edgardoc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,845 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 14,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000046 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,160 F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 88,240 | $0.00 Strike: $118.05 | $0.00 |
DisclosureSEC source: 0001735276-20-000030 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,240 Underlying: Common Stock · 88,240 shares Expires 2030-02-25 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2019. The reporting person also received 48,709 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 34,765 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001735276-20-000018 · edgardoc.xml · derivative · entry 9 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,295 Underlying: Common Stock · 34,765 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F9 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 502 | $133.42 | $66,976.84 |
DisclosureSEC source: 0001735276-20-000018 · edgardoc.xml · nonDerivative · entry 7 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,993 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F7 · price: Sale prices ranged from $133.40 to $133.43. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 18,065 | $132.81 | $2,399,212.65 |
DisclosureSEC source: 0001735276-20-000018 · edgardoc.xml · nonDerivative · entry 6 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,495 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F6 · price: Sale prices ranged from $132.37 to $133.24. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 6,887 | $131.61 | $906,398.07 |
DisclosureSEC source: 0001735276-20-000018 · edgardoc.xml · nonDerivative · entry 5 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,560 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F5 · price: Sale prices ranged from $131.30 to $132.24. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5,053 | $131.07 | $662,296.71 |
DisclosureSEC source: 0001735276-20-000018 · edgardoc.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,447 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F4 · price: Sale prices ranged from $130.29 to $131.28. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,586 | $129.33 | $205,117.38 |
DisclosureSEC source: 0001735276-20-000018 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,500 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F3 · price: Sale prices ranged from $129.16 to $129.90. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,672 | $128.62 | $343,672.64 |
DisclosureSEC source: 0001735276-20-000018 · edgardoc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,086 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. F2 · price: Sale prices ranged from $128.15 to $129.15. Read SEC document |
| February 20, 2020 Filed Feb 21, 2020 21:02 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 34,765 | $9.14 | $317,752.10 |
DisclosureSEC source: 0001735276-20-000018 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020. Read SEC document |
| February 14, 2020 Filed Feb 28, 2020 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GiftCommon stock | 1,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000026 · wf-form4_158292472045446.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,294 F1 · kind: This disposition reflects a gift of shares to a not-for-profit organization. Read SEC document |
| February 14, 2020 Filed Feb 28, 2020 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GiftCommon stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000026 · wf-form4_158292472045446.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,209 F1 · kind: This disposition reflects a gift of shares to a not-for-profit organization. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 17,498 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000122 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,996 Underlying: Common Stock · 17,498 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2017 (right to buy) · Derivative | 17,498 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000107 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Common Stock · 17,498 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 49,456 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · derivative · entry 6 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,456 shares Expires 2019-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. F6 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,870 | $80.31 | $150,179.70 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,993 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. F4 · price: Sale prices ranged from $80.28 to $80.44 Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 26,754 | $79.80 | $2,134,969.20 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,863 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. F3 · price: Sale prices ranged from $79.27 to $80.26 Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 20,832 | $78.92 | $1,644,061.44 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,617 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. F2 · price: Sale prices ranged from $78.27 to $79.26 Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 49,456 | $16.43 | $812,562.08 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000083 · edgardoc.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F3 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2015 (right to buy) · Derivative | 16,250 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-19-000083 · edgardoc.xml · derivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 16,250 shares Expires 2025-12-18 F2 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| July 11, 2019 Filed Aug 7, 2019 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 34 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000083 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 3,133 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GiftCommon stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-19-000011 · wf-form4_156054363018449.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,609 F1 · kind: This disposition reflects a gift of 5,000 shares to a not-for-profit organization. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000048 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F1 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. On June 6, 2019, the compensation committee of the Company determined the third performance criterion had been met on June 5, 2019 and the option vested as to one-quarter of the shares as of such date. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033625 · doc4.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-033625 · doc4.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033625 · doc4.xml · derivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878 Underlying: Common stock · 1,878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 8,919 | $0.00 Strike: $47.91 | $0.00 |
DisclosureSEC source: 0001209191-19-033625 · doc4.xml · derivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,919 Underlying: Common stock · 8,919 shares Expires 2029-05-29 F2 · derivative.exercise_date: This option was granted on May 29, 2019. The shares underlying this option vest as to 100% of the underlying shares on May 29, 2020. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 49,457 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0001553878-19-000002 · edgardoc.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,456 Underlying: Common Stock · 49,457 shares Expires 2019-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,457 options exercised and sold by the reporting person were due to expire on December 10, 2019. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 49,457 | $70.00 | $3,461,990.00 |
DisclosureSEC source: 0001553878-19-000002 · edgardoc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,993 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,457 options exercised and sold by the reporting person were due to expire on December 10, 2019. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 49,457 | $16.43 | $812,578.51 |
DisclosureSEC source: 0001553878-19-000002 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,457 options exercised and sold by the reporting person were due to expire on December 10, 2019. Read SEC document |
| April 09, 2019 Filed May 17, 2019 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 61 | $0.00 | $0.00 |
DisclosureSEC source: 0001553878-19-000002 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 3,099 F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 23:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $85.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000030 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2029-02-27 F1 · shares: Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 42,500 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 98,636 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001735276-18-000079 · edgardoc.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,636 shares Expires 2018-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a "net exercise" of outstanding stock options due to expire on December 8, 2018, as permitted under the governing ALNY stock incentive plan. These shares were withheld by ALNY for payment of the option exercise price and applicable tax withholding, based on the closing price of ALNY common stock on November 21, 2018. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 59,940 | $72.68 | $4,356,439.20 |
DisclosureSEC source: 0001735276-18-000079 · edgardoc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,993 F1 · kind: Represents a "net exercise" of outstanding stock options due to expire on December 8, 2018, as permitted under the governing ALNY stock incentive plan. These shares were withheld by ALNY for payment of the option exercise price and applicable tax withholding, based on the closing price of ALNY common stock on November 21, 2018. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 98,636 | $21.35 | $2,105,878.60 |
DisclosureSEC source: 0001735276-18-000079 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a "net exercise" of outstanding stock options due to expire on December 8, 2018, as permitted under the governing ALNY stock incentive plan. These shares were withheld by ALNY for payment of the option exercise price and applicable tax withholding, based on the closing price of ALNY common stock on November 21, 2018. Read SEC document |
| October 18, 2018 Filed Nov 26, 2018 21:11 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | OtherCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-18-000079 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 3,038 F2 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F2 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 20:56 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-18-000073 · edgardoc.xml · derivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.